Lv1
20 积分 2024-11-25 加入
Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression
1个月前
已完结
T-Cell Characteristics Impact Response and Resistance to T-Cell–Redirecting Bispecific Antibodies in Multiple Myeloma
3个月前
已完结
The bone marrow immune ecosystem shapes daratumumab acquired resistance in plasma cell myeloma
3个月前
已完结
Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma
3个月前
已完结
Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
3个月前
已完结
Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myeloma
3个月前
已完结
Experience of Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multicenter Study from Türkiye
5个月前
已关闭
An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma
6个月前
已完结
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
9个月前
已完结
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
9个月前
已完结
皖公网安备34019202002308
